Adam V Patterson
Overview
Explore the profile of Adam V Patterson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
1414
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ashoorzadeh A, Mowday A, Guise C, Silva S, Bull M, Abbattista M, et al.
Pharmaceuticals (Basel)
. 2022 Feb;
15(2).
PMID: 35215297
PR-104A is a dual hypoxia/nitroreductase gene therapy prodrug by virtue of its ability to undergo either one- or two-electron reduction to its cytotoxic species. It has been evaluated extensively in...
12.
Jackson-Patel V, Liu E, Bull M, Ashoorzadeh A, Bogle G, Wolfram A, et al.
Front Pharmacol
. 2022 Feb;
13:803602.
PMID: 35211015
Hypoxia-activated prodrugs are bioactivated in oxygen-deficient tumour regions and represent a novel strategy to exploit this pharmacological sanctuary for therapeutic gain. The approach relies on the selective metabolism of the...
13.
Lu X, Smaill J, Patterson A, Ding K
J Med Chem
. 2021 Dec;
65(1):58-83.
PMID: 34962782
Small molecule covalent kinase inhibitors (CKIs) have entered a new era in drug discovery, which have the advantage for sustained target inhibition and high selectivity. An increased understanding of binding...
14.
Abbattista M, Ashoorzadeh A, Guise C, Mowday A, Mittra R, Silva S, et al.
Pharmaceuticals (Basel)
. 2021 Dec;
14(12).
PMID: 34959631
PR-104 is a phosphate ester pre-prodrug that is converted in vivo to its cognate alcohol, PR-104A, a latent alkylator which forms potent cytotoxins upon bioreduction. Hypoxia selectivity results from one-electron...
15.
Singleton D, Mowday A, Guise C, Syddall S, Bai S, Li D, et al.
Cancer Gene Ther
. 2021 Nov;
29(7):1021-1032.
PMID: 34837065
Advances in the field of cancer immunotherapy have stimulated renewed interest in adenoviruses as oncolytic agents. Clinical experience has shown that oncolytic adenoviruses are safe and well tolerated but possess...
16.
van der Wiel A, Jackson-Patel V, Niemans R, Yaromina A, Liu E, Marcus D, et al.
Mol Cancer Ther
. 2021 Oct;
20(12):2372-2383.
PMID: 34625504
Hypoxia-activated prodrugs (HAP) are a promising class of antineoplastic agents that can selectively eliminate hypoxic tumor cells. This study evaluates the hypoxia-selectivity and antitumor activity of CP-506, a DNA alkylating...
17.
Omran Z, Guise C, Chen L, Rauch C, Abdalla A, Abdullah O, et al.
Molecules
. 2021 Jul;
26(11).
PMID: 34206005
Phenanthroindolizidines, such as antofine and tylophorine, are a family of natural alkaloids isolated from different species of They are characterized by interesting biological activities, such as pronounced cytotoxicity against different...
18.
Fu Z, Mowday A, Smaill J, Hermans I, Patterson A
Cells
. 2021 Apr;
10(5).
PMID: 33923305
The magnitude of the host immune response can be regulated by either stimulatory or inhibitory immune checkpoint molecules. Receptor-ligand binding between inhibitory molecules is often exploited by tumours to suppress...
19.
Deng W, Chen X, Jiang K, Song X, Huang M, Tu Z, et al.
ACS Med Chem Lett
. 2021 Apr;
12(4):647-652.
PMID: 33859803
Covalent kinase inhibitors are rapidly emerging as a class of therapeutics with clinical benefits. Herein we report a series of selective 2-aminopyrimidine-based fibroblast growth factor receptor 4 (FGFR4) inhibitors exploring...
20.
Mowday A, Dubois L, Kubiak A, Chan-Hyams J, Guise C, Ashoorzadeh A, et al.
Cancer Gene Ther
. 2021 Feb;
29(2):178-188.
PMID: 33558701
Necrosis is a typical histological feature of solid tumours that provides a selective environment for growth of the non-pathogenic anaerobic bacterium Clostridium sporogenes. Modest anti-tumour activity as a single agent...